Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 13, 2025, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time). Investors and interested parties can access the webcast through Regeneron's website investor section. A replay and transcript will be available on the company's website for at least 30 days after the presentation.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha annunciato la sua prossima presentazione alla 43ª Conferenza Annuale J.P. Morgan sulla Sanità. La presentazione è in programma per il 13 gennaio 2025, alle 14:15 ora del Pacifico (17:15 ora orientale). Gli investitori e le parti interessate possono accedere al webcast attraverso la sezione investitori del sito web di Regeneron. Una registrazione e una trascrizione saranno disponibili sul sito dell'azienda per almeno 30 giorni dopo la presentazione.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha anunciado su próxima presentación en la 43ª Conferencia Anual de J.P. Morgan sobre Atención Médica. La presentación está programada para el 13 de enero de 2025, a las 2:15 p.m. hora del Pacífico (5:15 p.m. hora del Este). Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección para inversores en el sitio web de Regeneron. Una repetición y la transcripción estarán disponibles en el sitio web de la compañía durante al menos 30 días después de la presentación.
레제너론 제약(Regeneron Pharmaceuticals, NASDAQ: REGN)이 제43회 JP모건 헬스케어 컨퍼런스에서의 발표를 예고했습니다. 발표는 2025년 1월 13일 태평양 표준시 오후 2시 15분(동부 표준시 오후 5시 15분)으로 예정되어 있습니다. 투자자와 관심 있는 분들은 레제너온의 웹사이트 투자자 섹션을 통해 웹캐스트에 접속할 수 있습니다. 발표 후 최소 30일 동안 회사 웹사이트에서 재생 및 전사본을 이용할 수 있습니다.
Regeneron Pharmaceuticals (NASDAQ: REGN) a annoncé sa prochaine présentation lors de la 43e Conférence Annuelle J.P. Morgan sur la Santé. La présentation est prévue pour le 13 janvier 2025, à 14h15 heure du Pacifique (17h15 heure de l'Est). Les investisseurs et les parties intéressées peuvent accéder au webinaire via la section investisseurs du site Web de Regeneron. Une rediffusion et un transcript seront disponibles sur le site de l'entreprise pendant au moins 30 jours après la présentation.
Regeneron Pharmaceuticals (NASDAQ: REGN) hat seine bevorstehende Präsentation auf der 43. Jahreshauptversammlung der J.P. Morgan Healthcare Conference angekündigt. Die Präsentation ist für den 13. Januar 2025 um 14:15 Uhr pazifischer Zeit (17:15 Uhr östlicher Zeit) geplant. Investoren und interessierte Parteien können über den Investorenbereich der Website von Regeneron auf das Webcast zugreifen. Eine Aufzeichnung und ein Transkript werden für mindestens 30 Tage nach der Präsentation auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
Corporate Communications
Christina Chan
914.847.8827
christina.chan@regeneron.com
FAQ
When is Regeneron (REGN) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Regeneron's (REGN) J.P. Morgan Healthcare Conference presentation?
How long will Regeneron's (REGN) 2025 J.P. Morgan Conference presentation replay be available?
Which annual J.P. Morgan Healthcare Conference will Regeneron (REGN) present at in 2025?
